ArriVent BioPharma (AVBP) Accumulated Expenses (2023 - 2026)

ArriVent BioPharma has disclosed Accumulated Expenses across 4 years of filings, most recently posting $14.1 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $14.1 million, up 811.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 million (up 811.81% YoY), and the FY2025 annual result was $20.0 million, up 50.02% from the prior year.
• Accumulated Expenses came in at $14.1 million for Q1 2026 at ArriVent BioPharma, down from $20.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $20.0 million in Q4 2025 to a low of $1.0 million in Q1 2024.
• The 4-year median for Accumulated Expenses is $10.6 million (2024), against an average of $9.6 million.
• Across the five-year window, Accumulated Expenses advanced 4.48% in 2025 and soared 811.81% in 2026, its largest moves.
• ArriVent BioPharma's Accumulated Expenses stood at $3.4 million in 2023, then surged by 297.55% to $13.3 million in 2024, then jumped by 50.02% to $20.0 million in 2025, then declined by 29.37% to $14.1 million in 2026.
• The last three Accumulated Expenses figures came in at $14.1 million (Q1 2026), $20.0 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.